Pfizer 2008.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: Panic disorder with or without agoraphobia according to DSM IV Method of diagnosis: no information provided Age: range = 18 ‐ 64 years, mean and SD not provided Sex: sertraline: female = 113, male = 44; paroxetine: female = 109, male = 53 Location: Japan; setting unclear Co‐morbidities: "patients with bipolar disorder, schizophrenia, delusional disorder, epilepsy, MDD, OCD, seasonal affective disorder or GAD were excluded; patients who concurrently have depression/depressive state, anxiety disorder and generalized anxiety disorder may be included if the primary diagnosis is identified to be panic disorder" Rescue medication: none
Interventions	Participants were randomly assigned to either: (1) sertraline arm (n = 157) Duration: 12 weeks Treatment Protocol: flexible dosage, range = 25 ‐ 100 mg (2) paroxetine arm (n = 164) Duration: 12 weeks Treatment Protocol: flexible dosage, range = 10 ‐ 30 mg
Outcomes	Time points for assessment: Outcomes: 1. Panic and Agoraphobia Scale 2. Clinical Global Impression Improvement Score (CGI‐I) 3. frequency of panic attacks 4. Hamilton Rating Scale for Anxiety (HAMA)
Notes	Date of study: May 2008 ‐ February 2010 Funding source: Pfizer Declarations of interest among the primary researchers: not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Allocation: randomized"
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Masking: double‐blind (subject, investigator)"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Masking: double‐blind (subject, investigator)"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"Last Obsevation Carried Forward"
Selective reporting (reporting bias)	Low risk	All outcomes were reported.
Other bias	High risk	Sponsored by Pfizer; the role of the funder in planning, conducting and writing the study is not discussed.